Limited stability of thiopurine metabolites in blood samples: Relevant in research and clinical practise

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 19, 2010, Pages 1437-1442

  de Graaf, P ^a   Vos, R M ^a   de Boer, N H K ^a   Sinjewel, A ^a   Jharap, B ^a   Mulder, C J J ^a   van Bodegraven, A A ^a   Veldkamp, A I ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

6 Mercaptopurine; 6 Methylmercaptopurine; 6 Thioguanine; 6 Thioguanine nucleotides; Azathioprine; Chemical stability; Clinical pharmacology; Inflammatory bowel disease; Patient blood samples; Therapeutic drug monitoring

Indexed keywords

6-MERCAPTOPURINE; 6-THIOGUANINE; 6-THIOGUANINE NUCLEOTIDES; BLOOD SAMPLES; CLINICAL PHARMACOLOGY; INFLAMMATORY BOWEL DISEASE; THERAPEUTIC DRUG MONITORING;

BLOOD; CAPILLARY TUBES; DRUG PRODUCTS; METABOLISM; METABOLITES; NUCLEOTIDES; PATIENT MONITORING; REFRIGERATION; SELF ASSEMBLY;

CHEMICAL STABILITY;

6 THIOGUANINE NUCLEOTIDE; DRUG METABOLITE; MERCAPTOPURINE; METHYLMERCAPTOPURINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG MONITORING; ENTERITIS; ENVIRONMENTAL TEMPERATURE; ERYTHROCYTE; FREEZING; HUMAN; HUMAN CELL; MOLECULAR STABILITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; ROOM TEMPERATURE; STORAGE;

6-MERCAPTOPURINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMANS; INFLAMMATORY BOWEL DISEASES; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; STATISTICS, NONPARAMETRIC; THIOGUANINE;

EID: 77952104055     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.03.004     Document Type: Article

References (34)

1. Sandborn W., Sutherland L., Pearson D., May G., Modigliani R., and Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. 2 (2000) CD000545
2. Timmer A., McDonald J.W., and Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 1 (2007 Jan 24) CD000478
3. Fraser A.G., Orchard T.R., and Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50 (2002) 485-489
4. Lichtenstein G.R., Abreu M.T., Cohen R., and Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 (1996) 940-987
5. Marathias V.M., Sawicki M.J., and Bolton P.H. 6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation. Nucleic Acids Res. 27 (1999) 2860-2867
6. Fairchild C.R., Maybaum J., and Kennedy K.A. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem. Pharmacol. 35 (1986) 3533-3541
7. Somerville L., Krynetski E.Y., Krynetskaia N.F., Beger R.D., Zhang W., Marhefka C.A., Evans W.E., et al. Structure and dynamics of thioguanine-modified duplex DNA. J. Biol. Chem. 278 (2003) 1005-1011
8. Swann P.F., Waters T.R., Moulton D.C., Xu Y.Z., Zheng Q., Edwards M., and Mace R. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273 (1996) 1109-1111
9. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., Lehr H.A., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111 (2003) 1133-1145
10. Poppe D., Tiede I., Fritz G., Becker C., Bartsch B., Wirtz S., Strand D., et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176 (2006) 640-651
11. Quéméneur L., Gerland L.M., Flacher M., Ffrench M., Revillard J.P., and Genestier L. Differential control of cell cycle, proliferation and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J. Immunol. 170 (2003) 4986-4995
12. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., Targan S.R., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122 (2002) 904-915
13. Wright S., Sanders D.S., Lobo A.J., and Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 53 (2004) 1123-1128
14. Dubinsky M.C. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy and safety. Clin. Gastroenterol. Hepatol. 2 (2004) 731-743
15. Cuffari C., Hunt S., and Bayless T.M. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol. Ther. 14 (2000) 1009-1014
16. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Théorêt Y., and Seidman E.G. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118 (2000) 705-713
17. Belaiche J., Desager J.P., Horsmans Y., and Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand. J. Gastroenterol. 36 (2001) 71-76
18. Goldenberg B.A., Rawsthorne P., and Bernstein C.N. The utility of 6- thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am. J. Gastroenterol. 99 (2004) 1744-1748
19. Wusk B., Kullak-Ublick G.A., Rammert C., von Eckardstein A., Fried M., and Rentsch K.M. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur. J. Gastroenterol. Hepatol. 16 (2004) 1407-1413
20. Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J. Chromatogr. 423 (1987) 169-178
21. Dervieux T., and Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin. Chem. 44 (1998) 551-555
22. Shipkova M., Armstrong V.M., Wieland E., and Oellerich M. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin. Chem. 49 (2003) 260-268
23. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17 (2000) 1551-1557
24. Graaf P., Boer de., de N.K.H., Jharap B., Mulder C.J.J., Bodegraven A.A., and Veldkamp A.I. Stability of thiopurine metabolites: a potential analytical bias. Clin. Chem. 54 (2008) 216-218
25. Pike M.G., Franklin C.L., Mays D.C., Lipsky J.J., Lowry P.W., and Sandborn W.J. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J. Chromatogr. B Biomed. Sci. Appl. 757 (2001) 1-9
26. Sauviat M., and Bolon M. Stability of thiopurine metabolites and thiopurine methyltransferase activity in human blood. Ther. Drug Monit. 27 (2005) 213
27. Cuffari C., Hunt S., and Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48 (2001) 642-646
28. Achkar J.P., Stevens T., Easley K., Brzezinski A., Seidner D., and Lashner B. Indicators of clinical response to treatment with sixmercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 10 (2004) 339-345
29. Wright S., Sanders D.S., Lobo A.J., and Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 53 (2004 Aug) 1123-1128
30. Hindorf U., Lyrenäs E., Nilsson A., and Schmiegelow K. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand. J. Gastroenterol. 39 (2004) 1105-1112
31. Lowry P.W., Franklin C.L., Weaver A.L., Pike M.G., Mays D.C., Tremaine W.J., Lipsky J.J., and Sandborn W.J. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 49 (2001) 665-670 [Abstract/Full Text]
32. Gupta P., Gokhale R., and Kirschner B.S. 6-Mercaptopurine metabolite levels in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 33 (2001) 450-454
33. Alexander Teml, Elke Schaeffeler, Herrlinger K.R., Ulrich Klotz, and Matthias Schwab. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin. Pharmacokinet. 46 (2007) 187-208
34. Reinshagen M., Schütz E., Armstrong V.W., Behrens C., von Tirpitz C., Stallmach A., Herfarth H., et al. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease. Clin. Chem. 53 (2007) 1306-1314